Stockscreener 앱 받기
11.15
5.89%
0.62
시간 외 거래:
11.16
0.010
+0.09%
전일 마감가:
$10.53
열려 있는:
$9.46
하루 거래량:
19,370
Relative Volume:
0.03
시가총액:
$5.28M
수익:
-
순이익/손실:
$-15.42M
주가수익비율:
-6.0598
EPS:
-1.84
순현금흐름:
$-13.41M
1주 성능:
+2,376%
1개월 성능:
+3,199%
6개월 성능:
+1,224%
1년 성능:
+404.52%
1일 변동 폭
$9.45
$11.16
1주일 범위
$0.3105
$12.41
52주 변동 폭
$0.2701
$12.41
Indaptus Therapeutics Inc Stock (INDP) Company Profile
명칭
Indaptus Therapeutics Inc
전화
(646) 427-2727
주소
3 COLUMBUS CIRCLE, NEW YORK
INDP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
11.15 | 5.28M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc 주식(INDP)의 최신 뉴스
Indaptus Therapeutics (INDP) Secures $2.3M Through Convertible N - GuruFocus
Indaptus Therapeutics raises $2.3 million through convertible notes By Investing.com - Investing.com South Africa
Indaptus Therapeutics Announces Sale Of $2.3 Million In Private Placement Of Convertible Notes And Warrants - MarketScreener
Indaptus Therapeutics Completes $2.3M Private Placement - TipRanks
Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round - Nasdaq
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - The Manila Times
Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum - The Manila Times
Clinical-Stage Biotech Indaptus Raises $2.3M from Healthcare Investor to Advance Cancer Treatment Trials - Stock Titan
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Breakthrough Pediatric Cancer Drug Could Unlock $155M FDA Voucher as OS Therapies Pursues RMAT Status - Stock Titan
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Estrella's $3.35M Funding Accelerates Novel T-Cell Therapy Trial for Non-Hodgkin's Lymphoma - Stock Titan
INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com India
Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
BNY Mellon Credit Fund's Last Distribution: $2.00 Payout Coming Before August Liquidation - Stock Titan
Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus
INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus
Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView
Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView
Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Stock Titan
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference - Stock Titan
Loar Holdings Q1 2025 Earnings Call: How to Join the May 13 Investor Presentation - Stock Titan
Luminar Reveals Major Business Overhaul: Strategic Restructuring and Cost Cuts Coming with Q1 Earnings - Stock Titan
Mark Your Calendar: Millrose Properties Q1 2025 Earnings Coming May 14Key Details Here - Stock Titan
Sandisk Key Q3 Financial Results: How to Access the May 7 Earnings Call - Stock Titan
Healthcare Giant Concentra's $55M Pivot Deal Adds 200 Workplace Clinics Across 40 States - Stock Titan
BeiGene Earnings Preview: Q1 Results Coming May 7 as Company Transforms to BeOne Medicines - Stock Titan
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World
Claritev Earnings Preview: Q1 2025 Results Coming May 8What to Watch - Stock Titan
Fortune 500 Retail Giant QVC Group Sets Stage for Crucial Q1 2025 Earnings Reveal - Stock Titan
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan
$1 Million Winner: Berkshire Employee Nails 31 of 32 March Madness Picks - Stock Titan
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Inc (INDP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):